anacor pharmaceuticals inc (ANAC) Key Developments
Anacor Pharmaceuticals Appoints Wendell Wierenga as Class III Director
Sep 12 14
Anacor Pharmaceuticals, Inc. announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board. Dr. Wierenga is a seasoned pharmaceutical executive with broad experience in all aspects of research, drug discovery and drug development. From June 2011 until February 2014, Dr. Wierenga served as Executive Vice President, Research and Development of Santarus, Inc.
Anacor Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 03:30 PM
Sep 9 14
Anacor Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 03:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer, President, Chairman of Compensation Committee, Chairman of Transaction Committee and Member of Audit Committee.
Anacor Pharmaceuticals, Inc. Provides Financial Guidance for the Remainder of the Year 2014
Aug 7 14
Anacor Pharmaceuticals, Inc. provided financial guidance for the remainder of the year 2014. Contract revenue related to neglected disease partnerships is expected to continue to be approximately $3 million per quarter. Interest expense will continue to be approximately $1.1 million per quarter in 2014. The company currently expects that the company will have at least $110 million in cash at year end 2014.
Anacor Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 7 14
Anacor Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenue was $2.931 million against $3.424 million a year ago. Loss from operations was $23.425 million against $11.808 million a year ago. Net loss was $24.508 million or $0.58 per diluted share against $14.096 million or $0.36 per diluted share a year ago. The decrease in contract revenues as compared to the same period in 2013 was primarily due to a decrease in revenues from collaborations with Lilly, GlaxoSmithKline LLC and not-for-profit organizations for neglected diseases, partially offset by an increase in revenues for research services performed under contract with the Gates Foundation and the addition of revenues under contract with DTRA, which entered into in the fourth quarter of 2013.
For the six months, total revenue was $7.089 million against $5.132 million a year ago. Loss from operations was $43.53 million against $25.975 million a year ago. Net loss was $45.68 million or $109 per diluted share against $29.174 million or $0.78 per diluted share a year ago.
Anacor Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 03:30 PM
Aug 7 14
Anacor Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 03:30 PM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Geoffrey M. Parker, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.